DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today reported financial results for the quarter ended July 31, 2016.
Third quarter 2016 revenue was $482 million, an 8% increase compared to the third quarter of 2015. The increase was driven by continued growth in the underlying business across the entire network, both in the United States and abroad. Revenue in the third quarter of 2015 included $15 million related to the Banner Life Sciences (BLS) business, which was spun off from Patheon on July 31, 2015. Revenue in the third quarter, excluding the 2015 BLS revenue, grew 11% on a year-over-year basis.
Third quarter 2016 revenue was $482 million, an 8% increase compared to the third quarter of 2015. The increase was driven by continued growth in the underlying business across the entire network, both in the United States and abroad. Revenue in the third quarter of 2015 included $15 million related to the Banner Life Sciences (BLS) business, which was spun off from Patheon on July 31, 2015. Revenue in the third quarter, excluding the 2015 BLS revenue, grew 11% on a year-over-year basis.
